Cerebrolysin

Cerebrolysin is an injectable preparation of low-molecular-weight peptides and free amino acids produced by enzymatic breakdown of porcine brain tissue. It is registered as a medicine in parts of Europe, Asia, and Latin America, and it has been studied mainly in acute ischaemic stroke, traumatic brain injury, and dementia. It has no US marketing authorisation — a DailyMed search returns no label for it.

What makes this page different from most on this site is that the evidence is not thin; it is contradictory. Randomised trials and several meta-analyses report meaningful recovery benefits, while the 2023 Cochrane review of the same field concludes the opposite and flags a safety signal. Both bodies of literature are real, and a page that reports only one of them is not describing the drug.

The proposed mechanism is neurotrophic: the peptide fraction is said to mimic endogenous neurotrophic factor activity, supporting neuronal survival, neuroplasticity, and neurogenesis after injury. Unlike a single-molecule drug, Cerebrolysin has no defined active ingredient to assign an effect to, so mechanistic attribution is inherently approximate — the mixture's composition is a function of the manufacturing process rather than a stated structure.

This matters practically rather than academically. A recombinant neurotrophic factor could be assayed, dose-standardised, and studied for a receptor. A process-defined biological extract can only be characterised by the outcomes of trials on specific batches, which is why the clinical evidence carries all the weight here.

Where Cerebrolysin is registered, its uses centre on post-stroke recovery, traumatic brain injury, and cognitive decline. It does not appear as a recommended therapy in the stroke guidelines of countries where it is unlicensed, and the Cochrane review's conclusion is the reason major guideline bodies have not adopted it.

It is not a nootropic in the consumer sense. No controlled trial has tested cognitive enhancement in healthy adults; the entire research base concerns recovery from neurological injury, using multi-week courses of clinician-administered infusions.

The commonly described effects are local injection reactions, allergic phenomena, dizziness, and headache. Two quantitative findings are more useful than that list, and they disagree:

• The CARS trial described Cerebrolysin as safe and well tolerated, with discontinuation in 3.8% of participants (Muresanu et al., Stroke 2016), and a 2025 meta-analysis of 14 randomised trials found serious adverse events comparable to control (RR 1.08, 95% CI 0.84–1.40) and mortality similar (RR 0.86, 95% CI 0.68–1.09) (Patel et al., Cureus 2025).

• The 2023 Cochrane review found non-fatal serious adverse events increased: RR 2.39 (95% CI 1.10–5.23), rising to RR 2.87 (95% CI 1.24–6.69) in the two trials using the 30 mL over 10 days schedule (1,189 participants). Total serious adverse events were RR 1.16 (95% CI 0.81–1.66) and fatal events RR 0.90 (95% CI 0.59–1.38) (Ziganshina et al., Cochrane Database Syst Rev 2023).

A doubling of non-fatal serious adverse events, with a confidence interval that excludes 1, is the single most important safety number published on this compound, and it is absent from most pages that discuss it.

Cerebrolysin is a ready-made solution given intravenously or intramuscularly, in volumes far larger than typical peptide injections, which is why higher doses require dilution and infusion rather than a syringe.

Cerebrolysin ships as a ready-to-use sterile solution in ampoules or vials, not as a lyophilised powder for reconstitution. That single practical fact separates it from nearly every other compound catalogued here.

Because it is a process-defined biological extract rather than a synthetic molecule, provenance carries more weight than usual: there is no reference standard against which an independent buyer could verify a vial, and no US label defining its composition. In the trials it was never given as a standalone intervention — CARS combined it with a standardised rehabilitation programme, so the published effect is Cerebrolysin plus rehabilitation versus placebo plus rehabilitation, not the drug alone.

• CARS (Stroke 2016, n=205 at day 90). Randomised, placebo-controlled, double-blind, multicentre. Primary outcome, the Action Research Arm Test at day 90, favoured Cerebrolysin with a Mann-Whitney effect size of 0.71 (95% CI 0.63–0.79, P<0.0001); a multivariate analysis across 12 outcome measures gave 0.62 (Muresanu et al.).

• CARS-1 and CARS-2 pooled (Neurol Sci 2017, n=442). ARAT effect size 0.62 (P<0.0001) and NIHSS at days 14–21 effect size 0.59 (P<0.002), with a number-needed-to-treat of 7.1 (95% CI 4–22) for clinically relevant early neurological improvement (Guekht et al.).

• 2025 meta-analysis (Cureus, 14 RCTs, n=2,884). Improved early neurological recovery on NIHSS (mean difference 1.39, 95% CI 0.53–2.25) and reduced haemorrhagic transformation (RR 0.55, 95% CI 0.32–0.92), but functional independence showed only a non-significant trend (RR 1.31, 95% CI 0.90–1.91) (Patel et al.).

• Cochrane 2023 (7 RCTs, 1,773 participants). Concluded that Cerebrolysin probably has no beneficial effect on preventing all-cause death and probably no beneficial effect on the total number of people with serious adverse events, while non-fatal serious adverse events were increased at RR 2.39 (95% CI 1.10–5.23) (Ziganshina et al.).

How to reconcile these. The positive results cluster on early, scale-based neurological and motor endpoints — ARAT and NIHSS scores at days 14 to 90 — while the negative conclusions concern hard outcomes: death and functional independence. Even the favourable 2025 meta-analysis found the functional independence result non-significant. Note also that CARS and its pooled meta-analysis share much of the same author group, so they are not independent confirmations of each other.

For deeper dives on this compound, see:

• Cerebrolysin benefits and areas of interest
• Cerebrolysin side effects and safety context
• Cerebrolysin dosing concepts (educational)
• Cerebrolysin research and evidence overview

What is Cerebrolysin made of? Enzymatically processed pig brain proteins — a mixture of low-molecular-weight peptides and free amino acids, not a single defined molecule. Its composition depends on the manufacturing process, which is why provenance matters more here than for a synthetic peptide.

Does Cerebrolysin work for stroke recovery? The evidence is genuinely split. CARS found a large effect on arm function at day 90 (effect size 0.71) and a 2025 meta-analysis of 14 trials found better early NIHSS recovery, but the 2023 Cochrane review concluded there is no demonstrated benefit on death or independence, and reported non-fatal serious adverse events at RR 2.39 (95% CI 1.10–5.23). Neither side of that dispute supports casual use.

Is Cerebrolysin FDA-approved? No. It is registered in parts of Europe, Asia, and Latin America, but has no US approval and no DailyMed label, and importing or selling it as a drug in the US is not authorised.

Is it a nootropic for healthy people? No controlled trial has tested cognitive enhancement in healthy adults. The research base is injury recovery — stroke, TBI, dementia — using multi-week courses of clinician-administered infusions.

How was it given in the trials? 30 mL daily by intravenous infusion for 21 days, beginning 24–72 hours after stroke, on top of a standardised rehabilitation programme. It is a ready-made solution in ampoules, not a powder to reconstitute.